Prognostic and Clinicopathologic Associations of<i>BRAF</i>Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study

Hong, Jin Woo; Lee, Suee; Kim, Dae Cheol; Kim, Ki Ho; Song, Ki Hoon

doi:10.5021/ad.2014.26.2.195

Cited by 26 publications

(20 citation statements)

References 24 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings showed that the BRAF V600 mutation rate is low in acral lentiginous melanoma (10.3%, 3/29). This result is in line with the rates determined in a number of studies conducted in Europe and the USA (16.7%), China (13.5%), Korea (19.4%) and Japan(18.8%) . Acral lentiginous melanoma, the most common subtype of melanoma in Asian individuals, exhibits different genetic alterations and biological behavior compared with other subtypes.…”

Section: Discussionsupporting

confidence: 89%

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan

Huang

Kuo

et al. 2016

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan

Huang

Kuo

et al. 2016

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…These data suggest that BRAF mutation is predictive for biological aggressiveness. In contrast with other reports [7], we did not observe a correlation between BRAF mutation status and patient age.…”

Section: Discussioncontrasting

confidence: 86%

“…However, although several studies have confirmed the association between TERT promoter mutation status and behavior of melanoma, no data have been reported regarding a possible effect of the coexistence of a TERT promoter mutation with other molecular alterations commonly detected in cutaneous melanoma. BRAF mutations represent a valuable prognostic marker in some types of tumor [32,33], but its importance as prognostic marker in melanoma is still unclear [7][8][9][10][11]. Additional studies are required to establish whether or not BRAF mutation status is correlated with clinicopathological factors and poor prognosis in melanoma.…”

Section: Discussionmentioning

confidence: 99%

“…Specific inhibitors that block the BRAF-activated pathway are used in clinical practice for a personalized molecular-targeted approach [5]. Whether or not BRAF mutations are of prognostic significance in the natural course of the disease is controversial, as correlations between BRAF mutation status and clinicopathological features and clinical outcome are still uncertain [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

et al. 2015

View full text Add to dashboard Cite

The recently described telomerase reverse transcriptase (TERT) promoter mutations are recurrent in cutaneous melanoma. Several authors have described an association between these molecular alterations, some histological parameters, and patient survival. BRAF mutations are very frequent in melanoma, but their actual role in the evolution of the disease is still unclear. Here, we investigated the relationship of TERT promoter mutations and BRAF mutations with the most relevant clinicopathological parameters, individually and coexisting, in order to evaluate their role as independent prognostic markers and to determine the effect of their coexistence. A TERT promoter alteration was found in 20 of 53 cases (38 %), significantly associated with histological type, increasing tumor thickness and mitotic rate, more advanced pathologic tumor (pT) stage, and absence of regression. A BRAF mutation was found in 21 of 53 cases (40 %), significantly associated with tumor thickness and presence of metastases in the sentinel lymph node. Coexistence of a TERT promoter and BRAF mutation was detected in 11 of 53 cases (21 %). This was associated with increasing thickness, high mitotic rate, lymph node metastasis, presence of ulceration, and absence of regression. Coexistence of a mutation in the TERT promoter and in the BRAF gene correlated with more prognostically relevant factors than either mutation alone. Our data lead us to hypothesize that TERT promoter and BRAF mutations cooperate in cutaneous melanoma. Further studies in larger cohorts of patients are needed to investigate how this synergistic effect is involved in the evolution of the disease.

show abstract

“…Also, a study by Hughahl et al (22) revealed the association between higher rates of BRAF V600 immunohistochemistry expression and increased tumour thickness, presence of ulceration and higher rates of mitosis. Conversely, several papers have declared that the BRAF V600 mutation has no impact on clinicopathological features or survival (22)(23)(24)(25)(26). Although there was no significant correlation in the present study, the patients with the BRAF V600 mutation were younger than the patients with wild-type BRAF, and NM was detected more commonly in BRAF V600-mutated patients.…”

Section: Discussioncontrasting

confidence: 53%

Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Can¹,

Taştekin²,

Yalta³

et al. 2018

TJPATH

View full text Add to dashboard Cite

Objective: BRAF is the most common mutation in melanoma. The most common subtype is BRAF V600E, followed by V600K. Initially, the authors aimed to investigate whether clinicopathological features of melanoma are associated with BRAF mutations. We then aimed to present the relationships between the clinicopathological features and the mutated subtype (V600E vs V600K). Material and Method:61 patients with metastatic malignant melanoma (affecting the lymph node or other distant sites) were selected. Patient data regarding age at the time of diagnosis, sex, metastatic site (lymph node, distant metastasis or both) and primary tumour site were obtained from the hospital's database. Tissue samples containing at least 30% tumour cells were isolated from the specimens of 61 patients (24 samples from primary tumours and 37 from metastatic foci) for BRAF analysis. Comparisons between the BRAF V600 mutation and clinicopathological and histopathological features were performed.Results: BRAF V600 mutation was detected in 34 (55.7%) patients. The subtype was BRAF V600E in 22 (64.7%) patients, BRAF V600K in 11(32.4%) patients and BRAF V600R in 1(2.9%) patient. The crucial results of the present study may be summarized as follows: i) BRAF V600 mutation was more common in older patients and tumors with BRAF V600 mutation revealed necrosis and LVI more commonly than wild-type tumors, ii) BRAF V600K mutation was more common in older patients and BRAF V600K mutated tumors exhibited ulceration more commonly than tumors with BRAF V600E mutation (close to significant). Conclusion:The BRAF V600 mutation may have interactions with prognostic clinicoptahological features of melanoma including necrosis and lymphovascular invasion. V600K mutation may be more common than expected and may have different associations with properties of the tumor such as tumor ulceration and patient age. Investigation of the mutated subtype of the BRAF gene may therefore reveal more detailed data about the management of melanoma and may also prevent missing of candidates for BRAF inhibitor therapies.

show abstract

Prognostic and Clinicopathologic Associations ofBRAFMutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study

Cited by 26 publications

References 24 publications

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey

Contact Info

Product

Resources

About